Current Report Filing (8-k)
September 11 2017 - 3:37PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
September 11, 2017
PEREGRINE PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its
charter)
Delaware
|
|
001-32839
|
|
95-3698422
|
(State of other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
14282 Franklin Avenue, Tustin, California 92780
|
(Address of Principal Executive Offices)
|
|
|
|
|
|
Registrant’s telephone number, including area code:
(714) 508-6000
|
|
Not Applicable
|
(Former name or former address, if changed since last report)
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2 below):
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
ý
Soliciting material pursuant to Rule 14A-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933(
§
230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (
§
240.12b-2
of this chapter).
o
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
o
Item 8.01 Other
Events.
On September 11, 2017,
Peregrine Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the appointment of Roger J. Lias,
Ph.D. as the new president of Avid Bioservices, Inc., the Company’s wholly-owned contract development and manufacturing organization
subsidiary, and his appointment to the Company’s Board of Directors. A copy of the press release is attached hereto as Exhibit
99.1.
Important Additional Information
Peregrine intends
to file a proxy statement with the Securities and Exchange Commission (SEC) in connection with the solicitation of proxies for
Peregrine’s 2017 Annual Meeting (Proxy Statement) with an associated WHITE proxy card. Peregrine, its directors and certain
of its executive officers will be participants in the solicitation of proxies from stockholders in respect of the 2017 Annual
Meeting. Information regarding the names of Peregrine’s directors and executive officers and their respective interests
in Peregrine by security holdings or otherwise is set forth in the Annual Report on Form 10-K of Peregrine, for the fiscal year
ended April 30, 2017, filed with the SEC on July 14, 2017, and Peregrine’s proxy statement for the 2016 Annual Meeting,
filed with the SEC on August 26, 2016. To the extent holdings of such participants in Peregrine’s securities are not reported,
or have changed since the amounts described, in the 2016 proxy statement, such changes have been reflected on Initial Statements
of Beneficial Ownership on Form 3 or Statements of Change in Ownership on Form 4 filed with the SEC. Details concerning the nominees
of Peregrine’s Board of Directors for election at the 2017 Annual Meeting will be included in the Proxy Statement. BEFORE
MAKING ANY VOTING DECISION, INVESTORS AND STOCKHOLDERS OF THE COMPANY ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH OR FURNISHED
TO THE SEC, INCLUDING THE COMPANY’S DEFINITIVE PROXY STATEMENT AND ANY SUPPLEMENTS THERETO, BECAUSE THEY WILL CONTAIN IMPORTANT
INFORMATION. Investors and stockholders will be able to obtain a copy of the definitive proxy statement and other documents filed
by Peregrine free of charge from the SEC’s website,
www.sec.gov
. Peregrine’s stockholders will also be able
to obtain, without charge, a copy of the definitive Proxy Statement and other relevant filed documents by directing a request
by mail to Peregrine, Corporate Secretary’s Office, 14282 Franklin Avenue, Tustin, CA 92780, by calling Peregrine’s
proxy solicitor, MacKenzie Partners, Inc., toll-free at (800) 322-2885, or from Peregrine’s website at
www.peregrineinc.com
.
Item 9.01 Financial
Statements and Exhibits.
(d) Exhibits.
The following material is filed as an exhibit to this Current Report on Form 8-K:
Exhibit
Number
99.1
Press Release issued September 11, 2017.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
PEREGRINE PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
Date: September 11, 2017
|
By:
/s/ Paul J. Lytle
|
|
Paul J. Lytle
|
|
Chief Financial Officer
|
EXHIBIT INDEX
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Sep 2023 to Sep 2024